Orla M. Gray

Belfast, NIR, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 21, 2026

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Journal: Brain : a journal of neurology
Published: March 12, 2026

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal: Journal of neurology
Published: November 01, 2025

Effects of Mind-body Movement Interventions for Managing Symptoms in People with Multiple Sclerosis: An Overview of Reviews.

Effects of Mind-body Movement Interventions for Managing Symptoms in People with Multiple Sclerosis: An Overview of Reviews.

Journal: Current neurology and neuroscience reports
Published: October 09, 2025

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal: Journal of neurology
Published: September 16, 2025

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 07, 2025

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: April 15, 2025

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Journal: JAMA neurology
Published: April 14, 2025

Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.

Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.

Journal: Multiple sclerosis and related disorders
Published: March 24, 2025

Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.

Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.

Journal: NPJ digital medicine
Published: February 13, 2025

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: July 20, 2024

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.

Journal: Journal of neurology
Published: May 04, 2024
Showing 1-12 of 49

Last Updated: 09/26/2026